These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32680595)

  • 1. Ten-Year Efficacy and Safety of Once-Daily Tacrolimus in Kidney Transplant: A Prospective Cohort Study.
    Parodi EL; La Porta E; Russo R; Marsano L; Bellino D; Paoletti E; Massarino F; Sofia A; Garibotto G; Esposito P; Murugavel A; Cappadona F; Fontana I; Viazzi F; Picciotto D
    Transplant Proc; 2020 Dec; 52(10):3112-3117. PubMed ID: 32680595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Effectiveness of Once-Daily, Prolonged-Release Tacrolimus in De Novo Kidney Transplant Recipients: 5-year, Multicenter Postmarketing Surveillance in Japan.
    Wakasugi N; Uchida H; Uno S
    Transplant Proc; 2018 Dec; 50(10):3296-3305. PubMed ID: 30577199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients.
    Sintes H; Sáez-Giménez B; Berastegui C; López-Meseguer M; Monforte V; Bravo C; Vima J; Gómez-Ollés S; Roman A
    Transplantation; 2018 Oct; 102(10):e439-e446. PubMed ID: 29965950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
    Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA
    Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature.
    Tran D; Vallée M; Collette S; Senécal L; Lafrance JP; Dandavino R; Boucher A
    Exp Clin Transplant; 2014 Aug; 12(4):323-7. PubMed ID: 24844288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion From Twice-Daily to Once-Daily Tacrolimus Among Egyptian Living-Donor Kidney Allograft Recipients: A Single-Center Experience.
    Bakr MA; Nagib AM; Abbas MH; Donia AF
    Exp Clin Transplant; 2019 Oct; 17(5):594-598. PubMed ID: 31050617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot Study Comparing the Efficacy, Safety, Convertibility, and Tacrolimus Trough Levels of Twice-Daily Tacrolimus (Prograf) to Once-Daily Tacrolimus (Advagraf) Among Standard-Risk Kidney Transplant Patients at the National Kidney and Transplant Institute.
    Danguilan RA; Lamban A; Pamugas GEP
    Transplant Proc; 2019 Oct; 51(8):2615-2619. PubMed ID: 31563241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of medication adherence with simplified once-daily immunosuppressive regimen in stable kidney transplant recipients: A prospective cohort study.
    Oh CK; Bang JB; Kim SJ; Huh KH; Kim SJ; Jeon JS; Han SY; Cho HR; Kwon YJ; Lee SH; Kim YS
    Asian J Surg; 2020 Jun; 43(6):660-667. PubMed ID: 31353239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Kidney Graft Recipients.
    Barreto P; Malheiro J; Vieira P; Pedroso S; Almeida M; Martins LS; Dias L; Henriques AC; Cabrita A
    Transplant Proc; 2016 Sep; 48(7):2276-2279. PubMed ID: 27742278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
    Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
    Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
    Mourad G; Glyda M; Albano L; Viklický O; Merville P; Tydén G; Mourad M; Lõhmus A; Witzke O; Christiaans MHL; Brown MW; Undre N; Kazeem G; Kuypers DRJ;
    Transplantation; 2017 Aug; 101(8):1924-1934. PubMed ID: 27547871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring.
    Kuypers DR; Peeters PC; Sennesael JJ; Kianda MN; Vrijens B; Kristanto P; Dobbels F; Vanrenterghem Y; Kanaan N;
    Transplantation; 2013 Jan; 95(2):333-40. PubMed ID: 23263559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from twice-daily to once-daily tacrolimus does not reduce intrapatient variability in tacrolimus exposure.
    Shuker N; Cadogan M; van Gelder T; Roodnat JI; Kho MM; Weimar W; Hesselink DA
    Ther Drug Monit; 2015 Apr; 37(2):262-9. PubMed ID: 25265255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from twice-daily to once-daily tacrolimus formulation in pediatric liver transplant recipients - a long-term prospective study.
    Quintero J; Juampérez J; Ortega J; Molino JA; Castells L; Bilbao I; Rodrigo C; Charco R
    Transpl Int; 2018 Jan; 31(1):38-44. PubMed ID: 28833714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single center, open-label, randomized pilot study to evaluate the safety and efficacy of tacrolimus modified release, Advagraf, versus tacrolimus twice daily, Prograf, in stable renal recipients (single).
    Yang SS; Choi JY; Cho WT; Park JB; Kim SJ
    Transplant Proc; 2015 Apr; 47(3):617-21. PubMed ID: 25891697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies.
    Vadcharavivad S; Saengram W; Phupradit A; Poolsup N; Chancharoenthana W
    Drugs; 2019 Dec; 79(18):1947-1962. PubMed ID: 31713065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily vs twice-daily tacrolimus for de novo living kidney transplantation patients including ABO/HLA compatible and incompatible: A randomized trial.
    Okumi M; Unagami K; Furusawa M; Kakuta Y; IIzuka J; Takagi T; Shirakawa H; Shimizu T; Omoto K; Inui M; Ishida H; Tanabe K
    Clin Transplant; 2018 Dec; 32(12):e13423. PubMed ID: 30318624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.